Drug Resistant Tumor Models

Nowadays, cancer tends to be managed as a chronic illness instead of a life-threatening disease, and this highlights the importance of drug resistance issues observed in tumors.

Drug resistance of tumors refers to the phenomenon where tumor cells in the patient’s body develop higher tolerability to the original therapy post a period of treatment, leading to a compromised therapeutic benefit and disease progression.

There various mechanisms of drug resistance, including efflux pump-mediated mechanisms of multidrug resistance (MDR) and efflux pump-independent drug resistance mechanisms.

The development of resistance may be due to the presence of pre-existing tumor cell populations which are not responsive to the original treatment. These populations can survive from the treatment and proliferate, leading to recurrence. It is also possible that, during the treatment process, tumor cells acquire the resistance out of genomic alternation, epigenetic changes, metabolism and immune regulations, etc.

The occurrence of drug resistance is both universal and individualized.

Resistant models are important preclinical research tools for drug resistance mechanism study and development of novel therapeutic drugs or strategies. In Medicilon, we can exploit drug exposure induction approach for drug resistant model development purpose.

• 
  Medicilon Drug Resistant Tumor Models
  Medicilon Drug Resistant Tumor Models

  Resistant models are important preclinical research tools for drug resistance mechanism study and development of novel therapeutic drugs or strategies. In Medicilon, we exploit drug exposure induction approach for drug resistant model development purpose. The following 4 drugs are selected for resistant model development: Herceptin, Osimertinib, Abemaciclib and Sotorasib.